Sign Up
Stories
ADvantage Therapeutics Appoints Professor Kuro-o and Provides Updates on Alzheimer's Disease Compound
Share
AMX0035 for PSP: Phase 3 Trial Commences
Advancements in Cancer Treatment and Mar...
Alpha Cognition's Business Update
ADOCIA Files 2023 Registration Document
AI Partnerships Drive Drug Discovery
ANJESO Drug Insight and Market Forecast
Overview
API
ADvantage Therapeutics appoints Professor Makoto Kuro-o to its Scientific Advisory Board. CEO Jeffrey Madden provides updates on the development of AD04™ for Alzheimer's Disease. The company aims to reduce aging effects by working on the klotho protein.
Ask a question
How does the development of AD04™ for Alzheimer's Disease contribute to the advancement of biotech?
What are the potential implications of ADvantage Therapeutics' work on the klotho protein for longevity?
What other areas of research and development is ADvantage Therapeutics focusing on?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage